Otsuka Pharmaceutical presented new phase 3b clinical trial results for SIMTRIYO (centanafadine) at Psych Congress 2026, demonstrating consistent improvements across ADHD symptoms, anxiety, executive function, and emotional dysregulation in adults with ADHD and comorbid anxiety disorders.
Researchers at the University of Warwick analyzed data from more than 1.9 million people across 23 studies and found that ADHD is associated with nearly double the odds of constipation, 58% higher odds of irritable bowel syndrome, and an almost 50% increase in overall gastrointestinal symptoms.
New research using brain imaging has revealed three distinct subtypes of ADHD, each associated with different underlying brain systems, co-occurring conditions, and learning challenges. The findings suggest that inattentive and hyperactive-impulsive symptom profiles follow separate neural pathways, potentially enabling more targeted treatment interventions.
Children born to mothers who used buprenorphine for opioid addiction during pregnancy show no greater risk of neurodevelopmental disorders like ADHD and autism compared to children whose mothers did not use the medication, providing reassurance about this critical treatment option.
